CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld its “Kreutzer-Limmer II” ’061 (EP 1352061) patent in oral proceedings held before the European Opposition Board. The ’061 patent is the first to be granted in Europe from the Kreutzer-Limmer II patent family, and includes broad claims covering methods of silencing approximately 130 disease genes with small interfering RNAs, or “siRNAs,” the molecules that mediate RNAi, which in this case comprise certain stabilizing design features and lengths of up to 49 nucleotides.
